FEATURED

• About 18% of American adults are now using a GLP-1 medication, up from roughly 14% in 2025, per FTI Consulting’s spring 2026 survey of 1,007 U.S. adults.
• JPMorgan estimates GLP-1 adoption could eliminate $30 billion to $55 billion in annual U.S. food and beverage industry sales by 2030 — a structural demand destruction event, not a cyclical softness.
• GLP-1 users consume approximately 21% fewer calories and spend roughly one-third less on grocery bills on average, per KPMG research.
• Around 23% of U.S. households currently have at least one member using a GLP-1 drug. By 2030, those households are projected to represent 35% of all food and beverage units sold in the U.S., per Circana.
• Novo Nordisk’s oral Wegovy pill launched in January 2026. Eli Lilly’s oral GLP-1 pill, Foundayo (orforglipron), received FDA approval on April 1, 2026 — with self-pay pricing starting at $149 per month and Medicare Part D access at $50 per month beginning July 1, 2026. The barrier to adoption just dropped considerably.
• GLP-1 users’ preference for smaller, more frequent eating occasions is restructuring the grocery basket: snacks, frozen foods, sugary beverages, and baked goods are the hardest-hit categories, while fresh produce, protein, and functional beverages are gaining share.
• Approximately 70% of GLP-1 users who consume fewer calories report snacking less, per EY-Parthenon — and snacking was the fastest-growing grocery segment before this shift began.

What Is Actually Happening Here

The GLP-1 story has been in the financial press for two years. What is still being underestimated is the velocity of the household penetration curve and what it means for companies that built their entire revenue models on volume consumption of exactly the categories users are now structurally avoiding.

One in five American adults. That is not a niche wellness trend. That is a demographic redistribution of caloric demand at a scale the food and beverage industry has never encountered. FTI Consulting’s spring 2026 survey found 18% current adoption — up four percentage points from 2025 alone. The trajectory, absent a major safety event or pricing collapse, points toward one in two eligible adults adopting a GLP-1 over the next decade, per FTI’s own projections.

What makes this different from every previous diet trend is permanence. Unlike Atkins, keto, or intermittent fasting, GLP-1 drugs suppress appetite pharmacologically. Users don’t drift back to old consumption patterns during the drug cycle. The structural demand shift is not behavioral — it is biochemical. And the household effect compounds it further: roughly half of GLP-1 users say their changed eating habits have spread to improved eating patterns across their entire households.

The access picture changed again in April. When Eli Lilly’s Foundayo cleared FDA review — a small-molecule pill that can be taken at any time, without food or water restrictions — it joined Novo Nordisk’s Wegovy pill on pharmacy shelves. Two oral options, both at $149 per month for cash-pay patients. Medicare Part D access for Foundayo starts July 1 at $50 per month. The friction that once kept adoption among middle-income households in check is rapidly eroding.

The Categories Exposed

FTI Consulting’s data is granular and worth reading carefully. Frozen foods show the single largest CPG dollar-spend impact in the first year of active GLP-1 use. Chips, sweet bakery goods, cookies, soft drinks, ice cream, candy, and chocolate all face substantial volume declines. Sugary drinks are contracting. Snack companies built on volume-per-household assumptions are running into a structural headwind that no amount of innovation cycling can fully reverse.

The alcohol angle is being systematically ignored in equity research. Around 20% of GLP-1 users report reduced alcohol consumption since starting the medication. FTI’s analysis estimates GLP-1 adoption could cut cumulative U.S. alcohol consumption by approximately 2.5% through 2035. For beer and hard seltzer — categories already under volume pressure — that is a meaningful additional structural headwind. The key point from FTI’s data: alcohol’s core product is inherently caloric, leaving manufacturers with few levers beyond low- and no-alcohol extensions. Premium spirits and flavor-forward mixed drinks are holding up better, creating a premiumization split within the alcohol sector itself.

Macro Context and Capital Rotation

The S&P 500 closed at 7,483 on July 2. Healthcare has been a quiet source of sector leadership this year. Within healthcare, GLP-1 innovation is actively reshaping pharmaceutical valuations — and the downstream ripple effects into consumer staples haven’t been fully absorbed into consensus models yet.

Capital has been rotating toward financials and communication services. Consumer staples, which typically trade at a defensiveness premium, are due for a re-examination as GLP-1 structural demand destruction becomes increasingly quantifiable in actual quarterly revenue numbers. The Q2 earnings season starts mid-July. Watch for volume commentary from snack and frozen food-heavy names specifically.

Who Benefits, Who Loses

The losing side of this trade is concentrated in a handful of large-cap packaged food names — companies with significant snack, frozen food, or sugary beverage exposure that haven’t yet seen the full GLP-1 impact in their reported numbers. When 35% of all food and beverage units are being purchased by households with at least one GLP-1 user by 2030, the volume math for volume-dependent business models is uncomfortable. Companies with low pricing power and high snack or sweet beverage exposure face the most direct earnings risk.

The winning side is more interesting. Companies positioned in protein, fresh produce, functional beverages, and portion-controlled, nutrient-dense formats are seeing GLP-1 users actively shift basket composition toward their categories. More than half of GLP-1 users are buying more fresh produce; roughly one-third reported increased purchases of yogurt, fresh chicken, and protein supplements. Retailers that have moved aggressively into GLP-1-friendly meal labeling — smaller, high-protein, high-fiber formats — are capturing wallet share from categories in structural decline.

The wellness and personal care adjacency is real and underpriced. Circana’s research shows self-care categories including skin care, fragrance, makeup, and beauty products are seeing upticks from GLP-1 users who are proud of their progress. That is a discretionary spending redirect — away from calories, toward appearance and wellness products. It’s a demand tailwind that most equity analysts haven’t yet connected to the GLP-1 adoption curve.

Scenario Modeling

Bull Case for GLP-1 Beneficiaries

Both oral GLP-1 options are now on shelves and priced for broader access. Medicare Part D coverage for Foundayo starts July 1 at $50 per month — a price point that brings a meaningful new population into the user base. Protein-forward food companies, functional beverage companies, and retailers with established GLP-1 product lines see consistent same-store sales outperformance against category peers. The valuation re-rating for these beneficiaries is still early. Most institutional models haven’t yet built in the structural demand gain on the winning side of this shift.

Base Case

GLP-1 adoption continues at a measured pace. The household penetration curve reaches 23-28% of U.S. households by 2027. Packaged food companies with snack and frozen food exposure guide Q3 and Q4 earnings conservatively, attributing volume softness to a combination of GLP-1 headwinds and macroeconomic pressure on the consumer. The market begins pricing a structural discount into the most exposed names. Winners in protein, functional beverages, and fresh formats outperform their sector peers by 600-800 basis points over the next four quarters.

Bear Case for Exposed Packaged Food Names

The 2030 projection of 30 million GLP-1 users proves conservative. With two oral formulations now available at consumer-friendly price points, the accessible market expands well beyond current forecasts. Companies that failed to pivot product pipelines early enough face sustained volume declines in their core categories with no offsetting revenue streams. The $30-55 billion in annual sales destruction JPMorgan models arrives faster than consensus currently expects, and earnings revisions across the packaged food sector become the defining negative catalyst for consumer staples in 2026 and 2027.

Active Trader Framework

The opportunity here is asymmetric in a specific way. The exposed names — those with heavy snack, sugary beverage, and frozen food revenue concentration — are still trading at valuations that embed significant volume stability assumptions. They have not adjusted for a world where 18% of adults eat structurally less of their core products, with that number heading higher on a clear trajectory. That is a valuation gap worth watching closely as Q2 and Q3 earnings season unfolds.

On the other side, companies with protein, fresh, or functional beverage exposure that have been growing into GLP-1 basket shifts but haven’t yet received full credit in analyst models represent a different kind of opportunity. The institutional ownership data on this rotation is still early.

For options traders, consumer staples heading into Q3 earnings — where GLP-1 volume headwinds may show up explicitly in guidance for the first time — is worth monitoring for asymmetric put positioning in names with the highest snack and frozen food revenue concentration. Implied volatility in consumer staples is typically lower than in tech, which can make downside protection cheaper relative to the risk being hedged.

One more thing worth sitting with: most analysis of GLP-1 impact focuses on the individual user. The household effect — the way one user’s changed eating habits ripple through the grocery basket of their entire household — is largely invisible in published research. If household-level demand destruction is being systematically undercounted, the $30-55 billion JPMorgan estimate may itself be understating the structural shift. That is a tail risk packaged food valuations are not fully accounting for. Keep that in mind as Q2 results start hitting in mid-July.